KB-0118

Overview

KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with K d values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF , IL-1β , and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > STAT

Product Information

• Catalog No.: HY-176535
• CAS No.: 2648377-08-4
• Molecular Formula: C17H11NO5
• Molecular Weight: 309.27
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source